Novartis BidCo AG
Novartis BidCo AG, a prominent subsidiary of Novartis AG, is headquartered in Switzerland (CH) and operates extensively across Europe and North America. Established in 1996, the company has made significant strides in the pharmaceutical industry, focusing on innovative medicines and advanced therapies. Specialising in areas such as oncology, cardiology, and immunology, Novartis BidCo AG is renowned for its commitment to research and development, delivering unique products that address unmet medical needs. The company has achieved notable market positioning, consistently ranking among the top global pharmaceutical firms. With a portfolio that includes groundbreaking treatments and a dedication to improving patient outcomes, Novartis BidCo AG continues to lead in the healthcare sector, driving advancements that shape the future of medicine.
DitchCarbon Score
How does Novartis BidCo AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis BidCo AG's score of 96 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis BidCo AG, headquartered in Switzerland (CH), currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family that includes Novartis AG, from which it inherits climate commitments and initiatives. Novartis AG has established various climate initiatives, including Science-Based Targets Initiative (SBTi) targets, CDP participation, and commitments to renewable energy through the RE100 initiative. These commitments are cascaded to Novartis BidCo AG at a level 2 relationship, indicating that the parent company’s sustainability strategies and targets influence its subsidiaries. While specific reduction targets or achievements for Novartis BidCo AG are not detailed, the overarching climate strategy from Novartis AG suggests a commitment to reducing carbon emissions across its operations. The absence of direct emissions data highlights the need for ongoing transparency and accountability in climate reporting within the organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis BidCo AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
